
Novel Natural and Synthetic Ligands of the Endocannabinoid System
In this review we describe recent advances in the chemistry of novel CB1/CB2 agonists, CB1 antagonists, selective CB2 agonists, fatty acid amide hydrolase inibitors, monoglyceride (MGL) and diglyceride (DAGL) inhibitors and cannabinoid-type agonists and antagonists of non CB1/CB2 receptors. In view of recent interest in the activities of fatty acid amides of amino acids (N-acyl amino acids) a list of this type of compounds was compiled and is presented as a Table. We conclude that further synthetic work based on both the plant cannabinoids and on the endocannabinoids may lead to novel therapeutics and that the identification and the elucidation of the biological profile of the myriad of endogenous N-acyl amino acids and related compounds may enhance the already wide spectrum of lipidomics.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics
Keywords: CB agonists; CB antagonists; DAGL; Endocannabinoids; FAAH; MGL
Document Type: Research Article
Affiliations: Institute for Drug Research,Hebrew University, Ein Kerem Campus, 91120 Jerusalem, Israel.
Publication date: May 1, 2010
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites